Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
March, 2026
March 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Abdulrahman Nasiri: Most Important Concepts and the Clinical Shift the COBRRA Trial Brings to Practice
Abdulrahman Nasiri/LinkedIn
Mar 14, 2026, 14:45

Abdulrahman Nasiri: Most Important Concepts and the Clinical Shift the COBRRA Trial Brings to Practice

Abdulrahman Nasiri, Assistant Professor of Medicine and Hematology at Imam Mohammad Ibn Saud Islamic University, shared a post on LinkedIn:

”In preparation for my upcoming Grand Rounds presentation, I’ve put together these slides translating the recent COBRRA trial (NEJM 2026) titled:

‘Settling the DOAC Debate in Acute VTE’.

For years, major clinical guidelines haven’t recommended one DOAC over another due to a lack of head-to-head randomized trials.

Here are the most important concepts and the clinical shift this trial brings to our practice:

  • Identical Efficacy: Both Apixaban and Rivaroxaban demonstrated an identical ~1% rate of recurrent VTE.
  • Superior Safety: Apixaban cut the risk of clinically relevant bleeding by more than half and drove an 84% reduction in major bleeding.
  • The Dosing Hypothesis: Why the difference? The bleeding divergence explodes in the first 3 weeks.

Rivaroxaban requires a high-dose induction phase that is three times longer than Apixaban (21 days vs. 7 days).

I am sharing the presentation here. Please feel free to use and adapt these slides for your own reference, clinical discussions, or teaching.”

Abdulrahman Nasiri

Stay updated with Hemostasis Today.

Abdulrahman Nasiri Acute Venous Thromboembolism Acute VTE Apixaban Apixaban vs Rivaroxaban COBRRA Trial DOAC Health Hematology Hemostasis Hemostasis Today Imam Mohammad Ibn Saud Islamic University internal medicine medical education Medicine NEJM New England Journal of Medicine Rivaroxaban thrombosis venous thromboembolism VTE
NewsFeed